

# Vittoria Mastromarino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/512740/vittoria-mastromarino-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

537  
citations

12  
h-index

23  
g-index

28  
ext. papers

664  
ext. citations

4  
avg, IF

3.67  
L-index

#	Paper	IF	Citations
24	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. <i>Clinical Science</i> , <b>2016</b> , 130, 57-77	6.5	149
23	IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. <i>Clinical Science</i> , <b>2011</b> , 120, 377-402	4.2	48
22	Polypharmacy in heart failure patients. <i>Current Heart Failure Reports</i> , <b>2014</b> , 11, 212-9	2.8	45
21	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. <i>Heart</i> , <b>2016</b> , 102, 602-9	5.1	34
20	Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 2421-9	3.2	28
19	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 432-9	3	27
18	Erythropoietin and the heart: facts and perspectives. <i>Clinical Science</i> , <b>2011</b> , 120, 51-63	6.5	26
17	Heart Failure Progression in Hypertrophic Cardiomyopathy - Possible Insights From Cardiopulmonary Exercise Testing. <i>Circulation Journal</i> , <b>2016</b> , 80, 2204-11	2.9	25
16	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , <b>2017</b> , 248, 326-332	3.2	18
15	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 509-18	2.3	15
14	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. <i>Clinical Cardiology</i> , <b>2015</b> , 38, 387-94	3.3	15
13	Novel Galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease. <i>Gene</i> , <b>2014</b> , 535, 365-9	3.8	13
12	Simultaneous Takotsubo syndrome in two sisters. <i>International Journal of Cardiology</i> , <b>2013</b> , 165, e49-50	3.2	12
11	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 125-131	3.2	11
10	Myocardial repolarization dispersion and late gadolinium enhancement in patients with hypertrophic cardiomyopathy. <i>Circulation Journal</i> , <b>2014</b> , 78, 1216-23	2.9	11
9	Erythropoietin in cardiac disease: effective or harmful?. <i>Journal of Cardiovascular Medicine</i> , <b>2013</b> , 14, 870-8	1.9	11
8	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	9

7	QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. <i>Journal of Cardiology</i> , <b>2017</b> , 70, 310-315	3	5
6	Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease. <i>American Journal of Cardiovascular Drugs</i> , <b>2015</b> , 15, 163-70	4	4
5	Spatial QT Dispersion Predicts Nonsustained Ventricular Tachycardia and Correlates with Confined Systodiastolic Dysfunction in Hypertrophic Cardiomyopathy. <i>Cardiology</i> , <b>2015</b> , 131, 122-9	1.6	4
4	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. <i>Current Signal Transduction Therapy</i> , <b>2012</b> , 7, 265-288	0.8	4
3	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2017</b> , 24, 243-253	2.9	3
2	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2017</b> , 24, 255-263	2.9	3
1	Restrictive cardiomyopathy and pseudoxanthoma elasticum skin lesions. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 2, e193-e195	1.9	